- Series C
Guardant Health is focused on developing breakthrough diagnostic technologies that can transform cancer from a silent killer into a manageable disease. Through a simple blood draw, Guardant360™ analyzes a patient’s current cancer genomics in order to better inform treatment decisions – all without a biopsy. Guardant Health was founded in 2011 by a team of serial entrepreneurs with expertise in next-generation sequencing, single-cell genomics and cancer diagnostics. The team is committed to positively and significantly impacting patient health through technology that addresses long-standing unmet needs in oncology.
Completed an IPO in 2018.